Verde Servicos Internacionais S.A. Decreases Stake in Intuitive Surgical, Inc. $ISRG

Verde Servicos Internacionais S.A. reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 51.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 16,446 shares of the medical equipment provider’s stock after selling 17,258 shares during the period. Intuitive Surgical accounts for about 3.0% of Verde Servicos Internacionais S.A.’s portfolio, making the stock its 16th largest position. Verde Servicos Internacionais S.A.’s holdings in Intuitive Surgical were worth $9,314,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Griffin Asset Management Inc. purchased a new position in Intuitive Surgical in the 4th quarter worth approximately $233,000. Fi3 FINANCIAL ADVISORS LLC purchased a new position in Intuitive Surgical in the 4th quarter worth approximately $340,000. Sierra Summit Advisors LLC increased its stake in Intuitive Surgical by 0.6% in the 4th quarter. Sierra Summit Advisors LLC now owns 24,451 shares of the medical equipment provider’s stock worth $13,848,000 after purchasing an additional 148 shares during the period. MJP Associates Inc. ADV increased its stake in Intuitive Surgical by 7.8% in the 4th quarter. MJP Associates Inc. ADV now owns 1,319 shares of the medical equipment provider’s stock worth $747,000 after purchasing an additional 95 shares during the period. Finally, Leonteq Securities AG bought a new stake in shares of Intuitive Surgical in the 4th quarter worth approximately $3,696,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction on Monday, May 11th. The stock was sold at an average price of $446.95, for a total transaction of $178,780.00. Following the completion of the transaction, the executive vice president owned 6,120 shares in the company, valued at approximately $2,735,334. The trade was a 6.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 119 shares of Intuitive Surgical stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $463.50, for a total value of $55,156.50. Following the transaction, the director owned 120 shares of the company’s stock, valued at $55,620. The trade was a 49.79% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,683 shares of company stock valued at $2,775,891 over the last ninety days. Insiders own 0.60% of the company’s stock.

Intuitive Surgical Stock Up 1.7%

NASDAQ ISRG opened at $449.03 on Thursday. Intuitive Surgical, Inc. has a twelve month low of $417.74 and a twelve month high of $603.88. The firm has a market capitalization of $159.03 billion, a PE ratio of 54.43, a P/E/G ratio of 3.53 and a beta of 1.51. The stock’s 50 day moving average is $460.63 and its 200 day moving average is $511.79.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. During the same period in the previous year, the company posted $1.81 earnings per share. The firm’s revenue was up 23.0% on a year-over-year basis. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ISRG. Evercore cut their price objective on Intuitive Surgical from $550.00 to $480.00 and set a “neutral” rating on the stock in a research report on Monday, April 6th. Zacks Research lowered Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Leerink Partners cut their price objective on Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Piper Sandler cut their price objective on Intuitive Surgical from $620.00 to $580.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 22nd. Finally, Jefferies Financial Group cut their price objective on Intuitive Surgical from $560.00 to $515.00 and set a “hold” rating on the stock in a research report on Wednesday, April 22nd. Nineteen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $579.33.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.